Production of high titer recombinant vesicular stomatitis virus in suspension cell culture

By transfecting packaged cells in suspended cell culture and introducing engineered rVSV, the problem of high production cost during adherent dependent cell culture is solved, and the production of high titer, replication-free rVSV is achieved, simplifying the process and improving the Scalability.

CN118891371APending Publication Date: 2024-11-01REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027021.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-11
Filing Date
2023-02-10
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

In the prior art, the production of recombinant vesicular stomatitis virus (rVSV) relies on adherent-dependent cell culture, resulting in labor-intensive and cost-effective production process, and is difficult to scale up.

Method used

Viral envelope glycoprotein is integrated into the virus by transfection of packaging cells to express viral envelope glycoproteins and introducing engineered rVSV at low infection pluralities, controlling temperature and time to produce replication-free rVSV. In the envelope.

Benefits of technology

The production of rVSV with high titer and no replication capability comparable to adherent cell culture in suspended cell culture is achieved, simplifying the production process, reducing costs, and improving the scalability of production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118891371A_ABST
    Figure CN118891371A_ABST
Patent Text Reader

Abstract

A method of producing a replication-free recombinant vesicular stomatitis virus (rVSV) in a suspension cell culture is disclosed. In some embodiments, the methods comprise inoculating a suspension cell culture medium with a packaging cell, transfecting the packaging cell with a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein, introducing an rVSV lacking a gene encoding a functional envelope glycoprotein into the suspension cell culture medium, and separating the rVSV from the suspension cell culture medium. And isolating the rVSV produced by the packaging cell, wherein the viral envelope glycoprotein is integrated into the viral envelope of the rVSV.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Reference to sequence listing

[0002] This application incorporates by reference a computer-readable sequence listing in ST.26 XML format, named 10976WO01_Sequence, created on February 3, 2023, and containing 9,944 bytes. Technical Field

[0003] The present invention relates to the production of recombinant viral particles, and in particular to methods for producing replication-incompetent recombinant vesicular stomatitis virus (rVSV) comprising viral envelope glycoproteins produced in transfected packaging cells. Background Art

[0004] The entry of all enveloped viruses requires a membrane fusion event mediated by one or more viral glycoproteins found on the surface of the viral lipid envelope. These envelope glycoproteins are responsible for binding the virus to the cell surface and inducing fusion of the viral envelope with the plasma membrane of the host cell or with the inner membrane after endocytosis of the virion.

[0005] Vesicular stomatitis virus (VSV) is a prototypical non-segmented negative-strand RNA virus belonging to the family Rhabdoviridae. Because VSV has a broad host range and robust replication in a variety of mammalian and insect cells, VSV has been widely used to study viral entry, replication, and assembly. One of the notable properties of VSV is that the VSV virion is not particularly selective for the type of membrane protein that can be integrated into the viral envelope. Early studies of cells co-infected with VSV and other enveloped viruses showed that VSV is easily pseudotyped. Pseudotypes have envelope proteins of heterologous viruses assembled into the VSV membrane. The ability to form pseudotypes may be due to the VSV budding mechanism, which has been shown to not require the VSV G protein. Studies on VSV assembly have led to the generation of recombinant VSV with a deletion in the glycoprotein (G) gene. This recombinant (rVSV-ΔG) has been used to generate VSV pseudotypes containing envelope glycoproteins of heterologous viruses. (Whitt, J Virol Methods, 169(2):365-374, 2010).

[0006] The production of rVSV mainly relies on anchorage-dependent cell culture technology. However, because the attachment-dependent culture process usually requires more steps and time than suspension culture, making the production more labor-intensive and costly, the scale-up of cell production using adherent cell-based production faces many challenges. Therefore, there is still a need to develop scalable propagation methods in which the production of recombinant VSV particles is sufficient for large-scale production. Summary of the invention

[0007] The present disclosure relates to methods for producing recombinant vesicular stomatitis virus (rVSV) in suspension cell culture, which produces virus titers comparable to adherent cell culture processes. The methods can be used, for example, to produce replication-incompetent rVSVs with envelope glycoproteins of any of a variety of enveloped viruses (e.g., SARS-CoV-2 or Ebola), which are used, for example, as pseudotyped viruses in viral antibody neutralization assays, or for vector-based vaccines.

[0008] In one aspect, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of packaging cells; (b) transfecting the packaging cells in the suspension cell culture medium with a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein; (c) introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of 0.001 to 3 to infect the population of packaging cells expressing the viral envelope glycoprotein, wherein the rVSV has been engineered so that the rVSV does not express a functional envelope glycoprotein; and (d) isolating the rVSV produced by the population of packaging cells 15 to 65 hours after infection, wherein the viral envelope glycoprotein is integrated into the viral envelope of the isolated rVSV.

[0009] In some embodiments, the MOI is between 0.001 and 1.0. In some embodiments, the MOI is between 0.005 and 0.05. In some cases, the MOI is between 0.008 and 0.012. In some cases, the MOI is about 0.01. In some cases, the MOI is between 0.01 and 2. In some cases, the MOI is between 0.01 and 1. In some cases, the MOI is between 0.8 and 1.2.

[0010] In some embodiments, the rVSV produced by the packaging cells is isolated at 40 to 50 hours after infection. In some cases, the rVSV produced by the packaging cells is isolated at 43 to 47 hours after infection. In some cases, the rVSV produced by the packaging cells is isolated at 20 to 30 hours after infection. In some cases, the rVSV produced by the packaging cells is isolated at 22 to 26 hours after infection.

[0011] In some embodiments, the packaging cell is a mammalian cell. In some cases, the packaging cell is a primate cell. In some cases, the packaging cell is a human cell. In some embodiments, the packaging cell is a human embryonic kidney (HEK) cell. In some cases, the HEK cell is a HEK293 cell. In some embodiments, the HEK293 cell is a HEK293F cell, a HEK293T cell, a HEK293SF cell, or a HEK293S cell. In some cases, the HEK293 cell is a HEK293F cell.

[0012] In some embodiments, the suspension cell culture medium is a serum-free, protein-free medium.

[0013] In some embodiments, the isolated rVSV is present in a concentration of at least 1 x 10 6 In some cases, the isolated rVSV was produced at an infectious titer of at least 1 x 10 7 pfu / mL. In some cases, the isolated rVSV was produced at an infectious titer of at least 1 x 10 8 pfu / mL. In some cases, the isolated rVSV was produced at an infectious titer of at least 5 x 10 8 pfu / mL. In some cases, the isolated rVSV was produced at an infectious titer of at least 1 x 10 9 In some cases, the rVSV isolated is produced at an infectious titer of 100 pfu / mL. In some cases, the rVSV isolated is produced at a titer comparable to the titer produced in the adherent cell-based control. In some cases, the rVSV isolated is produced at a titer that is at least 2 times greater than the titer produced in the adherent cell-based control. In some cases, the rVSV isolated is produced at a titer that is at least 3 times greater than the titer produced in the adherent cell-based control.

[0014] In some embodiments, the viral envelope glycoprotein is a vesicular stomatitis virus G protein. In some embodiments, the viral envelope glycoprotein is a class I fusion protein. In some embodiments, the viral envelope glycoprotein is a class II fusion protein. In some embodiments, the viral envelope glycoprotein is a class III fusion protein. In some embodiments, the viral envelope glycoprotein is a coronavirus spike protein. In some cases, the coronavirus spike protein is a spike protein of SARS-CoV-2. In some cases, the coronavirus spike protein comprises the amino acid sequence of SEQ ID NO: 1. In some cases, the coronavirus spike protein comprises the amino acid sequence of SEQ ID NO: 2. In some embodiments, the viral envelope glycoprotein is an Ebola virus glycoprotein. In some cases, the Ebola virus glycoprotein comprises the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4.

[0015] In some embodiments, the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpesvirus, a hepadnavirus, a poxvirus, a paramyxovirus, a rhabdovirus, a bunyavirus, a filovirus, a retrovirus, a hepatitis virus, an influenza A virus, and an influenza B virus.

[0016] In some embodiments of the method, transfecting the packaging cells comprises using a polyethyleneimine transfection reagent. In some embodiments of the method, transfecting the packaging cells comprises using a lipofectamine transfection reagent or a dedicated transfection reagent. (Polyplus, France) transfection reagent.

[0017] In some embodiments, when transfecting packaging cells, the cell culture medium contains at least 3 x 10 6 The cell density was 100 packaging cells / mL.

[0018] In some embodiments of the methods, transfecting the packaging cells comprises using a DNA concentration of at least 1.5 μg / mL. In some embodiments of the methods, transfecting the packaging cells comprises using a transfection reagent:DNA ratio of about 2 to about 3. In some embodiments of the methods, transfecting the packaging cells comprises using a transfection reagent:DNA ratio of about 2.5.

[0019] In some embodiments, the suspension cell culture medium is maintained at a certain temperature during inoculation and transfection, and the temperature of the suspension cell culture medium is reduced to a lower temperature when rVSV is introduced into the suspension cell culture medium. In some cases, the temperature is about 37°C. In some cases, the reduced temperature is about 32°C to about 36.5°C. In some cases, the reduced temperature is about 35.5°C. In some cases, the reduced temperature is about 34°C.

[0020] In some embodiments of the methods discussed herein, the suspension cell culture medium is not changed prior to introducing the rVSV into the suspension cell culture medium.

[0021] In one aspect, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells, wherein the temperature of the suspension cell culture medium is about 37°C; (b) transfecting the HEK293 cells in the suspension cell culture medium with a polyethyleneimine transfection reagent and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein; (c) lowering the temperature of the suspension cell culture medium to about 34°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.01 to infect a population of HEK293 cells expressing the viral envelope glycoprotein, wherein the rVSV has been engineered so that the rVSV does not express a functional envelope glycoprotein; and (d) isolating the rVSV produced by the packaging cell population 40 to 48 hours after infection, wherein the viral envelope glycoprotein is integrated into the viral envelope of the isolated rVSV.

[0022] In one aspect, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells, wherein the temperature of the suspension cell culture medium is about 37°C; (b) transfecting the HEK293 cells in the suspension cell culture medium with a polyethyleneimine transfection reagent and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein; (c) lowering the temperature of the suspension cell culture medium to about 34°C, and introducing rVSV into the suspension cell culture medium at an infection multiplicity (MOI) ratio of about 1 to infect a population of HEK293 cells expressing the viral envelope glycoprotein, wherein the rVSV has been engineered so that the rVSV does not express a functional envelope glycoprotein; and (d) isolating the rVSV produced by the packaging cell population 20 to 28 hours after infection, wherein the viral envelope glycoprotein is integrated into the viral envelope of the isolated rVSV.

[0023] In some embodiments, the viral envelope glycoprotein is a class I fusion protein, a class II fusion protein, or a class III fusion protein. In some embodiments, the viral envelope glycoprotein is a coronavirus spike protein. In some cases, the coronavirus is SARS-CoV-2. In some embodiments, the viral envelope glycoprotein is an Ebola virus glycoprotein. In some embodiments, the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of: flavivirus, alphavirus, togavirus, coronavirus, herpesvirus, hepadnavirus, poxvirus, paramyxovirus, rhabdovirus, bunyavirus, filovirus, retrovirus, hepatitis virus, influenza A virus, and influenza B virus.

[0024] In some embodiments, when transfecting HEK293 cells, the cell culture medium contains at least 3×10 6 The cell density was 100 HEK293 cells / mL.

[0025] In some embodiments of the methods, transfecting the HEK293 cells comprises using a DNA concentration of at least 1.5 μg / mL. In some embodiments of the methods, transfecting the HEK293 cells comprises using a transfection reagent:DNA ratio of about 2.5.

[0026] In some embodiments, the HEK293 cell is a HEK293F cell, a HEK293T cell, a HEK293SF cell, or a HEK293S cell. In some cases, the HEK293 cell is a HEK293F cell.

[0027] In various embodiments, any features or components of the embodiments discussed above or herein can be combined, and such combinations are included in the scope of the present disclosure. Any specified value discussed above or herein can be combined with another related value discussed above or herein to list a range, and the value represents the upper and lower limits of the range, and such ranges are included in the scope of the present disclosure.

[0028] Other embodiments will become apparent upon reading the ensuing detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 An exemplary suspension cell culture production schematic is shown. In the illustrated example, a recombinant VSV with a glycoprotein (G) gene deleted (rVSV-ΔG) is introduced into a suspension cell culture of packaging cells transfected with a plasmid containing a nucleic acid molecule encoding the VSV-G glycoprotein, such that upon viral replication and budding, the rVSV-ΔG incorporates the VSV-G glycoprotein into the viral envelope.

[0030] Figure 2Additional parameters of an exemplary production process in a small-scale bioreactor are shown (from top to bottom on day 2: temperature, agitation speed, pH and dissolved oxygen), the parameters are shown in Table 1 (Example 1).

[0031] Figure 3 The different parameters of the control sample and seven samples with a single parameter change are shown, as well as the viral titers obtained at 24, 33 and 48 hours post infection (hpi). The highlighted cells show the parameter changed for each corresponding sample. Infection was performed using a recombinant VSV-ΔG-Fluc / GFP virus stock (titer = 1.59E9). The comparative adherent cell system produced a viral titer of 9.3E8 pfu / mL.

[0032] Figure 4 Shown are time course titer data (plaque forming units / mL as a function of time (hours post infection)) corresponding to different production parameters (e.g., transfection, infection, culture and harvest conditions) for fifteen different runs shown in Table 2 (Example 2).

[0033] Figure 5A and Figure 5B The effects of different parameters of the suspension cell culture production process on viral titer (pfu / mL) are shown, including: (i) whether medium change is performed before infection; (ii) multiplicity of infection (MOI) ratio; (iii) transfection reagent type; (iv) temperature change during infection; and (v) harvest time in hours post infection (hpi).

[0034] Figure 6 An exemplary suspension cell culture production schematic for producing pseudotyped recombinant VSV (e.g., replacing VSV-G glycoprotein with coronavirus spike glycoprotein) is shown. In the illustrated example, a recombinant VSV (rVSV-ΔG) with a glycoprotein (G) gene deletion is introduced into a suspension cell culture of packaging cells transfected with a plasmid containing a nucleic acid molecule encoding a coronavirus spike glycoprotein, such that upon viral replication and budding, rVSV-ΔG incorporates the coronavirus spike glycoprotein into the viral envelope.

[0035] Figure 7 Results of luciferase assays are shown, showing that the spike glycoprotein pseudotyped rVSV (VSV-Spike) was produced at titers greater than 3-fold greater than those produced by adherent cell culture controls (adherent control D614G) and mock transfections (background). As shown, at 24 hours post-infection, the adherent control showed a titer of 1430 RLU, while the VSV-Spike showed a titer of approximately 5300 RLU. DETAILED DESCRIPTION

[0036] Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can vary. It should also be understood that the terminology used herein is only used for the purpose of describing specific embodiments, and is not intended to be limiting, because the scope of the present invention will be limited only by the appended claims.

[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. As used herein, the term "about" when used in reference to a specific recited numerical value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0038] As used herein, the terms "include," "includes," and "including" are intended to be non-limiting, and may be understood to mean "comprise," "comprises," and "comprising," respectively.

[0039] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All patents, applications and non-patent publications mentioned in this specification are incorporated herein by reference in their entirety.

[0040] Selected abbreviations

[0041] VSV – Vesicular Stomatitis Virus

[0042] rVSV – recombinant vesicular stomatitis virus

[0043] rVSV-ΔG – Recombinant vesicular stomatitis virus with glycoprotein (G) gene deleted

[0044] VSV-G – Vesicular Stomatitis Virus Envelope Glycoprotein (G)

[0045] HEK cells – human embryonic kidney cells

[0046] PFU – Plaque Forming Unit

[0047] MOI – Multiplicity of Infection

[0048] VLP – Virus-Like Particle

[0049] HPI – hours post infection

[0050] SARS-CoV-2 – Severe acute respiratory syndrome coronavirus 2

[0051] definition

[0052] "VSV" refers to any VSV strain or mutant form of VSV, including rVSV. VSV encompasses replication-incompetent VSV, such as VSV lacking the G glycoprotein.

[0053] "VSV-G" refers to the type III viral fusion protein that mediates fusion between the viral envelope of VSV and the host cell membrane to release the viral genome into the host cell.

[0054] "Replication-incompetent VSV" refers to a VSV in which the gene encoding the G envelope glycoprotein is deleted or mutated to produce a non-functional protein.

[0055] As used herein, the term "vector" or "plasmid" refers to a polynucleotide construct designed for transduction / transfection of one or more cell types. A vector or plasmid can be, for example, an "expression vector" or "expression plasmid" designed to express a nucleotide sequence in a host cell (e.g., a packaging cell).

[0056] The terms "polynucleotide" and "nucleic acid" used interchangeably herein refer to polymeric forms of nucleotides of any length, i.e., ribonucleotides or deoxyribonucleotides. These terms include single-stranded, double-stranded or triple-stranded DNA, genomic DNA, cDNA, genomic RNA, mRNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemical, biochemically modified, non-natural or derivatized nucleotide bases. The backbone of the polynucleotide may contain sugar and phosphate groups (as may be commonly present in RNA or DNA), or modified or substituted sugar or phosphate groups. In addition, double-stranded polynucleotides may be obtained from chemically synthesized single-stranded polynucleotide products by synthesizing complementary chains and annealing the chains under appropriate conditions or by synthesizing complementary chains de novo using DNA polymerase with appropriate primers.

[0057] The term "heterologous" refers to a combination of elements that are not naturally present in a virus or cell. For example, heterologous DNA refers to DNA that is not naturally located in a cell or in a chromosomal site of a cell. Heterologous DNA can include genes that are foreign to the cell. In the context of VSV, "heterologous glycoprotein" refers to a glycoprotein that is not present in the envelope of wild-type VSV.

[0058] As used herein, the terms "cell", "host cell", "cell culture" and the like are intended to include any single cell or cell culture that can be or has been a recipient of a virus, vector or exogenous nucleic acid molecule, polynucleotide and / or protein integration. It is also intended to include the progeny of a single cell. The cell is preferably a eukaryotic cell, but can be a prokaryotic cell, including but not limited to bacterial cells, yeast cells, animal cells and mammalian cells (e.g., mouse, rat, ape or human).

[0059] "Expression" includes transcription and / or translation.

[0060] "Encoded by" or "encoding" refers to a nucleic acid sequence that encodes a polypeptide sequence (i.e., an amino acid sequence) of a polypeptide encoded by a nucleic acid sequence. "Replicate" and "propagate" are used interchangeably and refer to the ability of the viruses of the present invention to reproduce or proliferate. These terms are fully understood in the art. For the purposes of the present invention, replication involves the production of VSV proteins and generally involves the propagation of VSV. Replication can be measured using assay standards in the art. "Replication" and "propagation" include any activity that directly or indirectly participates in the virus preparation process, including but not limited to viral gene expression; production of viral proteins, nucleic acids or other components; packaging of viral components into complete viruses; and cell lysis.

[0061] The term "multiplicity of infection" or "MOI" refers to the average number of viral particles that infect a single cell."MOI" is calculated by dividing the total number of viral plaque forming units (PFU) by the total number of cells infected.

[0062] The term "plaque" or "viral plaque" refers to a transparent, usually round plaque of lysed cells in an opaque layer of a cell culture. "Plaque forming unit" or "PFU" refers to the average number of infectious virus particles per unit volume. For example, if a virus solution has 100 PFU / ml, this means that every milliliter of the virus solution has 100 virus particles that can each form a plaque. PFU / mL is a conventional way to describe the concentration of a plaque-forming virus preparation. However, PFU is often used interchangeably with "infectious unit" or "IU" to represent the unit of infectious virus in a virus preparation.

[0063] The terms "culture fluid," "cell culture fluid," "cell culture media or cell culture medium," "culture medium," and / or "bioreactor fluid" are used interchangeably to refer to the culture medium or solution in which a cell culture is grown.

[0064] Cell suspension, suspension culture or suspension cell culture is a type of cell culture in which single cells or small aggregates of cells are allowed to function and propagate in an agitated growth medium, thereby forming a suspension. Suspension cell culture is in contrast to adherent cell culture, in which cells propagate while anchored to a physical matrix.

[0065] As used herein, the term "growth" refers to the in vitro propagation of viruses in various cells. The growth of viruses in cells in the laboratory includes inoculating cells with viruses, incubating to produce viruses, and then harvesting the cell culture medium containing viruses. Usually in a culture vessel (such as a flask or a bioreactor), virus-infected cells are grown in a growth medium and the culture is maintained in a cell incubator with a specific temperature, humidity and gas composition. However, culture conditions can vary according to cell types and can be changed to induce changes in cells or to support or enhance the production of viruses in cells.

[0066] As used herein, the term "harvesting" refers to the collection of cells or cell culture medium following infection of cells or cell lines with any of the viral strains or viral serotypes described herein in preparation for isolation and purification of the virus.

[0067] The terms "isolated" or "isolated" or "purified" or "purifying" mean removing a material from the environment in which it is produced. Thus, an isolated or purified virus or the process of isolating or purifying a virus refers to removing the virus from the cell culture and packaging cells in which it is produced.

[0068] As used in the context of the present invention, "gene" is a nucleotide sequence in a nucleic acid molecule (chromosome, plasmid, etc.) that is associated with a genetic function. A gene can encode an expressed product, such as a polypeptide or a polynucleotide (e.g., tRNA). Typically, a gene comprises a coding sequence (such as a polypeptide coding sequence) and a non-coding sequence (such as an intron or a regulatory sequence).

[0069] The terms "genetic modification" or "recombination" generally refer to the introduction of one or more mutations or deletions into the viral genome by any means known to those skilled in the art.

[0070] The terms "protein", "polypeptide" and "peptide" refer to polymers of amino acid residues and are not limited to a minimum length of the product. Thus, peptides, oligopeptides, dimers, multimers, etc. are included in this definition. This definition encompasses full-length proteins and fragments thereof. The term "amino acid" refers to natural and / or non-natural or synthetic amino acids, including D or L optical isomers and amino acid analogs. The one-letter and three-letter codes for each natural amino acid are known to those skilled in the art.

[0071] As used herein, the term "includes" and its cognates are used in their inclusive sense; that is, equivalent to the term "includes" and its corresponding cognates.

[0072] General Description

[0073] The present disclosure provides a method for producing recombinant vesicular stomatitis virus (rVSV) in a scalable suspension cell culture production system, which can produce virus titers comparable to adherent cell culture processes. Specifically, the method of the present disclosure includes a specific combination of culture, infection and harvest parameters to surprisingly produce high titers of replication-incompetent rVSV in suspension cell culture. The method can be used, for example, to produce replication-incompetent rVSV with envelope glycoproteins of any of a variety of enveloped viruses (e.g., SARS-CoV-2 or Ebola), which is used as, for example, a pseudotype virus in a viral antibody neutralization assay, or for a vector-based vaccine.

[0074] Method for producing replication-incompetent recombinant VSV

[0075] Aspects of the present disclosure relate to methods of producing replication-incompetent recombinant VSV particles that incorporate envelope glycoproteins expressed from a plasmid or other vector in a packaging cell from which the rVSV particle buds.

[0076] refer to Figure 1 Schematic diagram of an exemplary production process shown in FIG. 1 , a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV) may include: (a) inoculating a suspension cell culture medium (e.g., in a bioreactor) with a plurality of packaging cells (e.g., HEK293 cells) on day 0; (b) transfecting the packaging cells in the suspension cell culture medium with a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein on day 1 to produce a population of packaging cells expressing the viral envelope glycoprotein (VSV-G in Figure 1 However, it can be replaced by any viral envelope glycoprotein, such as Figure 6 (c) introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of 0.001 to 3 on day 2 to infect a population of packaging cells expressing viral envelope glycoproteins, wherein the rVSV has been engineered such that the rVSV does not express a functional envelope glycoprotein (e.g., rVSV-ΔG); and (d) following viral replication and budding, isolating the rVSV produced by the packaging cell population 15 to 65 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV (i.e., when the virus buds through the membrane of the packaging cell).

[0077] The packaging cell (or host cell) used for recombinant VSV production can be any cell in which VSV replicates, such as mammalian cells and some insect (e.g., Drosophila) cells. Immobilized cell lines or tumor cell lines can be used. Many cell lines well known in the art can be used. For example, such cell lines include but are not limited to BHK (baby hamster kidney) cells, CHO (Chinese hamster ovary) cells, HeLA (human) cells, mouse L cells, Vero (monkey) cells, African green monkey kidney (AGMK) cells, ESK-4, PK-15, EMSK cells, MDCK (Madin-Darby canine kidney) cells, MDBK (Madin-Darby bovine kidney) cells, HEK293 (human) cells and Hep-2 cells. Such cell lines can be publicly available from, for example, ATCC and other culture collections. In some embodiments, the packaging cell or host cell is a mammalian cell. In some cases, the packaging cell or host cell is a primate cell or a human cell. In some embodiments, the packaging cell or host cell is a human embryonic kidney (HEK) cell. In some cases, the HEK cell is a HEK293 cell and can be selected from a HEK293F cell, a HEK293T cell, a HEK293SF cell, and a HEK293S cell. In some embodiments, the packaging cell or host cell is a HEK293F cell. In some cases, the packaging cell or host cell is a HEK293F cell grown in suspension cell culture.

[0078] The culture medium (or production medium) used for suspension cell culture of packaging cells or host cells can be any suitable product. Preferably, the culture medium is free of animal-derived components, free of protein and chemically defined. An exemplary culture medium is CTS TM LV-MAX TM Production medium (ThermoFisher Scientific).

[0079] Transfection of packaging cells or host cells can be accomplished by any suitable method known in the art. In some embodiments, transfection is accomplished using a transfection reagent (to facilitate uptake of the vector or plasmid), such as a polyethyleneimine transfection reagent (e.g., PEI MAX TM ; Polysciences), liposome transfection reagents or Transfection reagent (Polyplus, France). Alternatively, plasmid DNA uptake can also be enhanced by electroporating the cells (applying a high voltage current for a few milliseconds to a tube containing cells and DNA).

[0080] In various embodiments, when the cell density of the packaging cells reaches a sufficient density, transfection of the vector or plasmid into a plurality of packaging cells or host cells is performed. In some embodiments, when the cell density reaches at least 3×10 6 In various embodiments, the cell density is at least about 1 x 10 6 cells / mL, at least about 1.5x10 6 cells / mL, at least about 2x10 6 cells / mL, at least about 2.5x10 6 cells / mL, at least about 3x10 6 cells / mL, at least about 3.5x10 6 cells / mL, at least about 4x10 6 cells / mL, at least about 4.5x10 6 cells / mL, or at least about 5x10 6 cells / mL.

[0081] In some cases, transfection of packaging cells or host cells is accomplished using a DNA concentration of at least 1.5 μg / mL. In various embodiments, the concentration of DNA contained in the vector or plasmid is at least about 0.5 μg / mL, at least about 0.6 μg / mL, at least about 0.7 μg / mL, at least about 0.8 μg / mL, at least about 0.9 μg / mL, at least about 1.0 μg / mL, at least about 1.1 μg / mL, at least about 1.2 μg / mL, at least about 1.3 μg / mL, at least about 1.4 μg / mL, at least about 1.5 μg / mL, at least about 1.6 μg / mL, at least about 1.7 μg / mL, at least about 1.8 μg / mL, at least about 1.9 μg / mL, at least about 2.0 μg / mL, at least about 2.5 μg / mL, at least about 3.0 μg / mL, at least about 3.5 μg / mL, at least about 4.0 μg / mL, at least about 5.5 μg / mL, or at least about 5.0 μg / mL.

[0082] In various embodiments, transfection is accomplished by using a transfection reagent:DNA ratio of about 1 to about 5. In some cases, the transfection reagent:DNA ratio is about 2 to about 3. In some cases, the transfection reagent:DNA ratio is 2.5. In various embodiments, the transfection reagent:DNA ratio is about 1, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, or about 5.0.

[0083] In various embodiments, the vector or plasmid transfected into the packaging cell (or host cell) comprises a nucleic acid molecule encoding a viral envelope glycoprotein, which may be a heterologous glycoprotein (i.e., a glycoprotein that is not normally produced by VSV). In some cases, the viral envelope glycoprotein is a vesicular stomatitis virus G protein. In some cases, the viral envelope glycoprotein is a class I fusion protein. In some cases, the viral envelope glycoprotein is a class II fusion protein. In some cases, the viral envelope glycoprotein is a class III fusion protein. In some embodiments, the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of: flavivirus, alphavirus, togavirus, coronavirus, herpesvirus, hepadnavirus, poxvirus, paramyxovirus, rhabdovirus, bunyavirus, filovirus, retrovirus, hepatitis virus, influenza A virus, and influenza B virus.

[0084] In various embodiments, the vector or plasmid transfected into the packaging cell (or host cell) comprises a nucleic acid molecule encoding a coronavirus spike glycoprotein (e.g., a spike protein from SARS-CoV-2). In some cases, the spike glycoprotein comprises the amino acid sequence of SEQ ID NO: 1. In some cases, the spike glycoprotein comprises the amino acid sequence of SEQ ID NO: 2.

[0085] In various embodiments, the vector or plasmid transfected into the packaging cell (or host cell) comprises a nucleic acid molecule encoding an Ebola virus glycoprotein. In some cases, the Ebola virus glycoprotein comprises the amino acid sequence of SEQ ID NO: 3. In some cases, the Ebola virus glycoprotein comprises the amino acid sequence of SEQ ID NO: 4.

[0086] In any of the various embodiments of the methods discussed herein, the suspension cell culture medium is not replaced prior to the introduction of the rVSV into the suspension cell culture medium (discussed below). Although replacing the culture medium prior to or immediately prior to infecting the packaging cells with the virus is generally considered advantageous for removing residual elements from the transfection process, the inventors surprisingly discovered that these advantages are mitigated under other factors (e.g., MOI and harvest time), such that replacing the culture medium can be avoided, thereby improving the scalability of the production process.

[0087] In various embodiments, infection of packaging cells (or host cells) with recombinant VSV (not expressing functional envelope glycoproteins) is performed by introducing the virus into a suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.001 to about 5. In some cases, the MOI is about 0.001 to about 0.5. In some cases, the MOI is about 0.001 to about 1. In some cases, the MOI is about 0.005 to about 3. In some cases, the MOI is about 0.005 to about 1.5. In some cases, the MOI is about 0.001 to about 0.1. In some cases, the MOI is about 0.005 to about 0.05. In some cases, the MOI is about 0.008 to about 0.012. In some cases, the MOI is about 0.01 ± 0.001. In some cases, the MOI is about 0.5 to about 1.5. In some cases, the MOI is about 0.8 to about 1.2. In some cases, the MOI is about 1 ± 0.1. In various embodiments, the MOI is about 0.001, 0.0015, 0.002, 0.0025, 0.003, 0.0035, 0.004, 0.0045, 0.005, 0.0055, 0.006, 0.0065, 0.007, 0.0075, 0.008, 0.0085, 0.009, 0.0095, 0.0 1. 0.011, 0.012, 0.013, 0.014, 0.015, 0.016, 0.017, 0.018, 0.019, 0.02, 0.0225, 0.025, 0.0275, 0.03, 0.0325, 0.035, 0.0375, 0.04, 0.0425, 0.045, 0.0475, or 0.5. In some cases, the MOI is about 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.05, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, or 5.

[0088] In the methods discussed herein, the suspension cell culture medium is maintained at a certain temperature during inoculation and transfection, and the temperature of the suspension cell culture medium is reduced to a lower temperature when the packaging cells are infected with rVSV. In some cases, the temperature of the suspension cell culture during inoculation and transfection is about 37 ° C, and is reduced to a temperature of about 32 ° C to about 36.5 ° C when infected or near infection (e.g., within 1 hour). In some cases, the temperature is reduced to about 35.5 ° C. In some cases, the temperature is reduced to about 34 ° C. In various embodiments, the temperature of the cell culture during inoculation and transfection is 36.6 ° C, 36.7 ° C, 36.8 ° C, 36.9 ° C, 37 ° C, 37.1 ° C, 37.2 ° C, 37.3 ° C, 37.4 ° C, 37.5 ° C, 37.6 ° C, 37.7 ° C, 37.8 ° C, 37.9 ° C or 38 ° C. In various embodiments, including those mentioned in the previous sentence, the reduced temperature is 32°C, 32.1°C, 32.2°C, 32.3°C, 32.4°C, 32.5°C, 32.6°C, 32.7°C, 32.8°C, 32.9°C, 33°C, 33.1°C, 33.2°C, 33.3°C, 33.4°C, 33.5°C, 33.6°C, 33.7°C, 33.8°C, 33.9°C, 34°C. , 34.1℃, 34.2℃, 34.3℃, 34.4℃, 34.5℃, 34.6℃, 34.7℃, 34.8℃, 34.9℃, 35℃, 35.1℃, 35.2℃, 35.3℃, 35.4℃, 35.5℃, 35.6℃, 35.7℃, 35.8℃, 35.9℃, 36℃, 36.1℃, 36.2℃, 36.3℃, 36.4℃ or 36.5℃.

[0089] In various embodiments, the infected packaging cells are cultured for a period of time before harvesting and isolating viral particles. In some embodiments, the rVSV particles produced by the packaging cells are isolated at about 40 to about 50 hours post infection (hpi). In some cases, the rVSV particles produced by the packaging cells are isolated at about 43 hpi to about 47 hpi. In various embodiments, the rVSV particles produced by the packaging cells are isolated at about 44 hpi or about 45 hpi. In some cases, at 40 hpi, 40.1 hpi, 40.2 hpi, 40.3 hpi, 40.4 hpi, 40.5 hpi, 40.6 hpi, 40.7 hpi, 40.8 hpi, 40.9 hpi, 41 hpi, 41.1 hpi, 41.2 hpi, 41.3 hpi, 41.4 hpi, 41.5 hpi, 41.6 hpi, 41.7 hpi, 41.8 hpi, 41.9 hpi, 42 hpi, 42.1 hpi, 42.2 hpi, 42.3 hpi, 42.4 hpi, 42.5hpi, 42.6hpi, 42.7hpi, 42.8hpi, 42.9hpi, 43hpi, 43.1hpi, 43.2hpi, 43.3hpi, 43.4hpi, 43.5hpi, 43.6hpi, 43.7hpi , 43.8hpi, 43.9hpi, 44hpi, 44.1hpi, 44.2hpi, 44.3hpi, 44.4hpi, 44.5hpi, 44.6hpi, 44.7hpi, 44.8hpi, 44.9hpi, 45hpi, 4 5.1hpi, 45.2hpi, 45.3hpi, 45.4hpi, 45.5hpi, 45.6hpi, 45.7hpi, 45.8hpi, 45.9hpi, 46hpi, 46.1hpi, 46.2hpi, 46.3hpi, 46.4hpi, 46.5hpi, 46.6hpi, 46.7hpi, 46.8hpi, 46.9hpi, 47hpi, 47.1hpi, 47.2hpi, 47.3hpi, 47.4hpi, 47.5hpi, 47.6hpi , 47.7 hpi, 47.8 hpi, 47.9 hpi, 48 hpi, 48.1 hpi, 48.2 hpi, 48.3 hpi, 48.4 hpi, 48.5 hpi, 48.6 hpi, 48.7 hpi, 48.8 hpi, 48.9 hpi, 49 hpi, 49.1 hpi, 49.2 hpi, 49.3 hpi, 49.4 hpi, 49.5 hpi, 49.6 hpi, 49.7 hpi, 49.8 hpi, 49.9 hpi or 50 hpi to isolate the rVSV particles produced by the packaging cells.In some cases, rVSV particles produced by packaging cells are isolated at about 15 hpi to about 35 hpi. In some cases, rVSV particles produced by packaging cells are isolated at about 20 hpi to about 30 hpi. In various embodiments, rVSV particles produced by packaging cells are isolated at about 24 hpi or about 25 hpi. In some cases, at 20 hpi, 20.1 hpi, 20.2 hpi, 20.3 hpi, 20.4 hpi, 20.5 hpi, 20.6 hpi, 20.7 hpi, 20.8 hpi, 20.9 hpi, 21 hpi, 21.1 hpi, 21.2 hpi, 21.3 hpi, 21.4 hpi, 21.5 hpi, 21.6 hpi, 21.7 hpi, 21.8 hpi, 21.9 hpi, 22 hpi, 22.1 hpi, 22.2 hpi, 22.3 hpi, 22.4 hpi, 22.5hpi, 22.6hpi, 22.7hpi, 22.8hpi, 22.9hpi, 23hpi, 23.1hpi, 23.2hpi, 23.3hpi, 23.4hpi, 23.5hpi, 23.6hpi, 23.7hpi , 23.8hpi, 23.9hpi, 24hpi, 24.1hpi, 24.2hpi, 24.3hpi, 24.4hpi, 24.5hpi, 24.6hpi, 24.7hpi, 24.8hpi, 24.9hpi, 25hpi, 2 5.1hpi, 25.2hpi, 25.3hpi, 25.4hpi, 25.5hpi, 25.6hpi, 25.7hpi, 25.8hpi, 25.9hpi, 26hpi, 26.1hpi, 26.2hpi, 26.3hpi, 26.4hpi, 26.5hpi, 26.6hpi, 26.7hpi, 26.8hpi, 26.9hpi, 27hpi, 27.1hpi, 27.2hpi, 27.3hpi, 27.4hpi, 27.5hpi, 27.6hpi , 27.7 hpi, 27.8 hpi, 27.9 hpi, 28 hpi, 28.1 hpi, 28.2 hpi, 28.3 hpi, 28.4 hpi, 28.5 hpi, 28.6 hpi, 28.7 hpi, 28.8 hpi, 28.9 hpi, 29 hpi, 29.1 hpi, 29.2 hpi, 29.3 hpi, 29.4 hpi, 29.5 hpi, 29.6 hpi, 29.7 hpi, 29.8 hpi, 29.9 hpi or 30 hpi. In some cases, the rVSV particles produced by the packaging cells are isolated at about 30 hpi to about 40 hpi.In some cases, at 30 hpi, 30.1 hpi, 30.2 hpi, 30.3 hpi, 30.4 hpi, 30.5 hpi, 30.6 hpi, 30.7 hpi, 30.8 hpi, 30.9 hpi, 31 hpi, 31.1 hpi, 31.2 hpi, 31.3 hpi, 31.4 hpi, 31.5 hpi, 31.6 hpi, 31.7 hpi, 31.8 hpi, 31.9 hpi, 32 hpi, 32.1 hpi, 32.2 hpi, 32.3 hpi, 32.4 hpi, 32.5hpi, 32.6hpi, 32.7hpi, 32.8hpi, 32.9hpi, 33hpi, 33.1hpi, 33.2hpi, 33.3hpi, 33.4hpi, 33.5hpi, 33.6hpi, 33.7hpi , 33.8hpi, 33.9hpi, 34hpi, 34.1hpi, 34.2hpi, 34.3hpi, 34.4hpi, 34.5hpi, 34.6hpi, 34.7hpi, 34.8hpi, 34.9hpi, 35hpi, 3 5.1hpi, 35.2hpi, 35.3hpi, 35.4hpi, 35.5hpi, 35.6hpi, 35.7hpi, 35.8hpi, 35.9hpi, 36hpi, 36.1hpi, 36.2hpi, 36.3hpi, 36.4hpi, 36.5hpi, 36.6hpi, 36.7hpi, 36.8hpi, 36.9hpi, 37hpi, 37.1hpi, 37.2hpi, 37.3hpi, 37.4hpi, 37.5hpi, 37.6hpi , 37.7 hpi, 37.8 hpi, 37.9 hpi, 38 hpi, 38.1 hpi, 38.2 hpi, 38.3 hpi, 38.4 hpi, 38.5 hpi, 38.6 hpi, 38.7 hpi, 38.8 hpi, 38.9 hpi, 39 hpi, 39.1 hpi, 39.2 hpi, 39.3 hpi, 39.4 hpi, 39.5 hpi, 39.6 hpi, 39.7 hpi, 39.8 hpi, 39.9 hpi or 40 hpi to isolate rVSV particles produced by the packaging cells.

[0090] VSV is usually secreted into the culture medium from the host cell or packaging cell. Therefore, separating the VSV product may include collecting from the cell culture fluid. In some cases, an affinity matrix, for example, may be used to separate the rVSV produced by the cell line. In short, the method of separating rVSV may include adding VSV to an affinity matrix to produce a bound VSV, washing the bound VSV, and eluting the VSV from the affinity matrix. The present disclosure encompasses a modified VSV comprising a non-naturally occurring fusion protein on the outer surface of the virus. The non-natural protein may be a fusion protein comprising an affinity tag and a viral envelope glycoprotein, or it may be derived from a packaging cell. The packaging cell line may be engineered to express one or more affinity tags on its plasma membrane, which will be acquired by the virus when the virus buds through the membrane. An example of an affinity tag is the use of a histidine residue that is bound to a fixed nickel column. Affinity tags also include antibodies. Other affinity purification schemes known in the art may be used, such as, but not limited to, batch processing, a solution of a virus and an affinity matrix, a matrix bound by centrifugal precipitation, and separation of the virus. Alternatively, VSV can be collected and purified from the culture supernatant, which can then be clarified to remove cell debris. One method of isolating and concentrating the virus is by concentrating the supernatant through a tangential flow membrane. The volume of the harvest can be further reduced by precipitation through a glycerol cushion and by concentrating on a cesium chloride or sucrose step gradient or other form of gradient.

[0091] In various embodiments, the suspension cell culture production methods of the present disclosure are performed with at least 1 x 10 6 In some cases, the suspension cell culture production methods of the present disclosure produce rVSV at an infectious titer of at least 1 x 10 7 pfu / mL. In some cases, the suspension cell culture production methods of the present disclosure produce rVSV at an infectious titer of at least 1 x 10 8 pfu / mL. In some cases, the suspension cell culture production methods of the present disclosure produce rVSV at an infectious titer of at least 5 x 10 8 pfu / mL. In some cases, the suspension cell culture production methods of the present disclosure produce rVSV at an infectious titer of at least 1 x 10 9 In various embodiments, the suspension cell culture production method disclosed herein produces rVSV at an infectious titer of at least 1 x 10 pfu / mL. 6 pfu / mL, 2x10 6 pfu / mL, 3x 10 6 pfu / mL, 4x 10 6 pfu / mL, 5x 10 6 pfu / mL, 6x 10 6pfu / mL, 7x 10 6 pfu / mL, 8x 10 6 pfu / mL, 9x 10 6 pfu / mL, 1x 10 7 pfu / mL, 2x 10 7 pfu / mL, 3x 10 7 pfu / mL, 4x 10 7 pfu / mL, 5x 10 7 pfu / mL, 6x 10 7 pfu / mL, 7x 10 7 pfu / mL, 8x 10 7 pfu / mL, 9x 10 7 pfu / mL, 1x 10 8 pfu / mL, 2x 10 8 pfu / mL, 3x 10 8 pfu / mL, 4x 10 8 pfu / mL, 5x 10 8 pfu / mL, 6x 10 8 pfu / mL, 7x 10 8 pfu / mL, 8x 10 8 pfu / mL, 9x 10 8 pfu / mL, 1x 10 9 pfu / mL, 2x 10 9 pfu / mL, 3x 10 9 pfu / mL, 4x 10 9 pfu / mL, 5x 10 9 pfu / mL, 6x 10 9 pfu / mL, 7x 10 9 pfu / mL, 8x 10 9 pfu / mL or 9x 10 9 rVSV was produced at infectious titers of pfu / mL.

[0092] In various embodiments, the suspension cell culture production methods of the present disclosure produce rVSV at an infectious titer that is at least comparable to the titer produced by an adherent cell culture control (which produces the same rVSV). In some cases, the suspension cell culture production methods of the present disclosure produce rVSV at an infectious titer that is at least 1.5 times, at least 2 times, at least 2.5 times, or at least 3 times greater than the titer produced by an adherent cell culture control (which produces the same rVSV).

[0093] Vesicular Stomatitis Virus (VSV)

[0094] VSV is a member of the Rhabdoviridae family, a negative-strand virus that replicates in the cytoplasm of infected cells, does not undergo genetic recombination or reassortment, has no known transformation potential, and does not integrate any part of its genome into the host. VSV comprises a genome of approximately 11 kilobases, which encodes five proteins, referred to as nucleocapsid (N), polymerase protein (L) and (P), surface glycoprotein (G) and peripheral matrix protein (M). The genome is tightly wrapped in the nucleocapsid (N) protein, and also comprises polymerase protein (L) and (P). After infecting cells, polymerase protein initiates transcription of five subgenomic viral mRNAs encoding viral proteins from the negative-sense genome. Polymerase protein is also responsible for packaging into the replication of the full-length viral genome in progeny virions. Matrix (M) protein is combined with RNA genome / nucleocapsid core (RNP) and is also combined with glycosylated (G) protein, which extends from the outer surface with a series of spike-like projections, and is responsible for combining with cell surface receptors and initiating infection processes. As discussed herein, the recombinant VSV can be the same as the VSV discussed above, except that the gene encoding the glycosylation (G) protein is deleted or the gene encoding the glycosylation (G) protein is mutated so as to produce a non-functional protein. The recombinant VSV used for infection, although not encoding a functional G glycoprotein, contains a G glycoprotein in its viral envelope.

[0095] After VSV attaches to receptors on the host surface through (G) protein, the virus penetrates the host and sheds the coat to release RNP particles. The polymerase protein carried by the virus binds to the 3' end of the genome, synthesizing the individual mRNAs encoding N, P, M and L in sequence, followed by the synthesis of negative-sense daughter genomes. The newly synthesized N, P and L proteins associate and form an RNP core in the cytoplasm, which binds to the plasma membrane region rich in M ​​protein and glycoprotein encoded by the transfected plasmid. Virus particles are formed, and then daughter viruses bud or release.

[0096] Any of the various VSV strains can be used in the methods of the present disclosure. VSV strains include Indiana, New Jersey, Piry, Colorado, Coccal, Chandipura, and San Juan strains. The complete nucleotide and deduced protein sequences of the VSV genome are known and available as Genbank VSVCG, accession number J02428, NCBI Seq ID 335873; published in Rose and Schubert, 1987, The Viruses: The Rhabdoviruses, Plenum Press, NY. Pages 129-166. The New Jersey strain of VSV is available from the American Type Culture Collection (ATCC) with ATCC accession number VR-159. The Indiana strain of VSV is available from ATCC with ATCC accession number VR-1421.

[0097] Exemplary Production Methods

[0098] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells (selected from HEK293F cells, HEK293T cells, HEK293SF cells or HEK293S cells), wherein the temperature of the suspension cell culture medium is about 36.6° C. to 37.4° C.; (b) transfecting the HEK293 cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein; cells to produce a packaging cell population expressing viral envelope glycoproteins; (c) lowering the temperature of the suspension cell culture medium to about 32.5°C to about 35.5°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.005 to about 0.015 to infect a HEK293 cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 40 to 48 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0099] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells (selected from HEK293F cells, HEK293T cells, HEK293SF cells or HEK293S cells), wherein the temperature of the suspension cell culture medium is about 36.8° C. to 37.2° C.; (b) transfecting the HEK293 cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein; 93 cells to produce a packaging cell population expressing viral envelope glycoproteins; (c) lowering the temperature of the suspension cell culture medium to about 33°C to about 35°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.008 to about 0.012 to infect a HEK293 cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 42 to 46 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0100] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells (selected from HEK293F cells, HEK293T cells, HEK293SF cells or HEK293S cells), wherein the temperature of the suspension cell culture medium is 37°C ± 0.1°C; (b) transfecting the HEK293 cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein; K293 cells to produce a packaging cell population expressing viral envelope glycoproteins; (c) lowering the temperature of the suspension cell culture medium to about 34°C ± 0.1°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.01 to infect a HEK293 cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 43 to 45 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0101] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.6°C to 37.4°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of: a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpesvirus, a hepatotropic virus, a cytomegalovirus ... DNA viruses, poxviruses, paramyxoviruses, rhabdoviruses, bunyaviruses, filoviruses, retroviruses, hepatitis viruses, influenza A virus and influenza B virus; (c) reducing the temperature of the suspension cell culture medium to about 32.5°C to about 35.5°C and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.005 to about 0.015 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 40 to 48 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0102] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.8°C to 37.2°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of: a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpesvirus, Hepadnavirus, poxvirus, paramyxovirus, rhabdovirus, bunyavirus, filovirus, retrovirus, hepatitis virus, influenza A virus and influenza B virus; (c) reducing the temperature of the suspension cell culture medium to about 33°C to about 35°C and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.008 to about 0.012 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 42 to 46 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0103] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is 37°C ± 0.1°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of: a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpes simplex virus, a toxins, hepadnaviruses, poxviruses, paramyxoviruses, rhabdoviruses, bunyaviruses, filoviruses, retroviruses, hepatitis viruses, influenza A virus and influenza B virus; (c) lowering the temperature of the suspension cell culture medium to about 34°C ± 0.1°C and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.01 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 43 to 45 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0104] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.6° C. to 37.4° C.; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a coronavirus spike protein (e.g., a spike protein of SARS-CoV-2), which optionally comprises SEQ ID NO: 1 or SEQ ID NO: 2. NO:2 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 32.5°C to about 35.5°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.005 to about 0.015 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 40 to 48 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0105] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.8° C. to 37.2° C.; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a coronavirus spike protein (e.g., a spike protein of SARS-CoV-2), which optionally comprises SEQ ID NO: 1 or SEQ ID NO: 2. NO:2 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 33°C to about 35°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.008 to about 0.012 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 42 to 46 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0106] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is 37°C ± 0.1°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a coronavirus spike protein (e.g., a spike protein of SARS-CoV-2), which optionally comprises SEQ ID NO: 1 or SEQ ID NO: 2. NO:2 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 34°C ± 0.1°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.01 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 43 to 45 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0107] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.6° C. to 37.4° C.; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is an Ebola virus glycoprotein, which optionally comprises SEQ ID NO: 3 or SEQ ID NO: 4. NO:4 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 32.5°C to about 35.5°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.005 to about 0.015 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 40 to 48 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0108] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.8° C. to 37.2° C.; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is an Ebola virus glycoprotein, which optionally comprises SEQ ID NO: 3 or SEQ ID NO: 4. NO:4 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 33°C to about 35°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.008 to about 0.012 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 42 to 46 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0109] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is 37°C ± 0.1°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is an Ebola virus glycoprotein, which optionally comprises SEQ ID NO: 3 or SEQ ID NO: 4. NO:4 amino acid sequence; (c) lowering the temperature of the suspension cell culture medium to about 34°C ± 0.1°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.01 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 43 to 45 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0110] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells (selected from HEK293F cells, HEK293T cells, HEK293SF cells or HEK293S cells), wherein the temperature of the suspension cell culture medium is about 36.6° C. to 37.4° C.; (b) transfecting the HEK293 cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein; 93 cells to produce a packaging cell population expressing viral envelope glycoproteins; (c) lowering the temperature of the suspension cell culture medium to about 32.5°C to about 35.5°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.5 to about 1.5 to infect a HEK293 cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 20 to 28 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0111] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells (selected from HEK293F cells, HEK293T cells, HEK293SF cells or HEK293S cells), wherein the temperature of the suspension cell culture medium is about 36.8° C. to 37.2° C.; (b) transfecting the HEK293 cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein; K293 cells to produce a packaging cell population expressing viral envelope glycoproteins; (c) lowering the temperature of the suspension cell culture medium to about 33°C to about 35°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.8 to about 1.2 to infect a HEK293 cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 22 to 26 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0112] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells (selected from HEK293F cells, HEK293T cells, HEK293SF cells or HEK293S cells), wherein the temperature of the suspension cell culture medium is 37°C ± 0.1°C; (b) transfecting the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein; HEK293 cells to produce a packaging cell population expressing viral envelope glycoproteins; (c) lowering the temperature of the suspension cell culture medium to about 34°C ± 0.1°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 1 to infect a HEK293 cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 23 to 25 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0113] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.6°C to 37.4°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of: a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpesvirus, Hepadnavirus, poxvirus, paramyxovirus, rhabdovirus, bunyavirus, filovirus, retrovirus, hepatitis virus, influenza A virus and influenza B virus; (c) reducing the temperature of the suspension cell culture medium to about 32.5°C to about 35.5°C and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.5 to about 1.5 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 20 to 28 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0114] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.8°C to 37.2°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of: a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpesvirus (c) reducing the temperature of the suspension cell culture medium to about 33°C to about 35°C and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.8 to about 1.2 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 22 to 26 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0115] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is 37°C ± 0.1°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a packaging cell population expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of: a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpesvirus, a (c) reducing the temperature of the suspension cell culture medium to about 34°C ± 0.1°C and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 1 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 23 to 25 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0116] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.6° C. to 37.4° C.; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a coronavirus spike protein (e.g., a spike protein of SARS-CoV-2), which optionally comprises SEQ ID NO: 1 or SEQ ID NO: 2. NO:2 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 32.5°C to about 35.5°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.5 to about 1.5 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 20 to 28 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0117] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.8° C. to 37.2° C.; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a coronavirus spike protein (e.g., a spike protein of SARS-CoV-2), which optionally comprises SEQ ID NO: 1 or SEQ ID NO: 2. NO:2 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 33°C to about 35°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.8 to about 1.2 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 22 to 26 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0118] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is 37°C ± 0.1°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is a coronavirus spike protein (e.g., a spike protein of SARS-CoV-2), which optionally comprises SEQ ID NO: 1 or SEQ ID NO: 2. NO:2 amino acid sequence; (c) lowering the temperature of the suspension cell culture medium to about 34°C ± 0.1°C and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 1 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 23 to 25 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0119] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.6° C. to 37.4° C.; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is an Ebola virus glycoprotein, which optionally comprises SEQ ID NO: 3 or SEQ ID NO: 4. NO:4 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 32.5°C to about 35.5°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.5 to about 1.5 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 20 to 28 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0120] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is about 36.8° C. to 37.2° C.; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is an Ebola virus glycoprotein, which optionally comprises SEQ ID NO: 3 or SEQ ID NO: 4. NO:4 amino acid sequence; (c) reducing the temperature of the suspension cell culture medium to about 33°C to about 35°C, and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.8 to about 1.2 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 22 to 26 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0121] In one embodiment, the present disclosure provides a method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293F cells, wherein the temperature of the suspension cell culture medium is 37°C ± 0.1°C; (b) transfecting the HEK293F cells in the suspension cell culture medium with a transfection reagent (e.g., a polyethyleneimine transfection reagent) and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein, wherein the viral envelope glycoprotein is an Ebola virus glycoprotein, which optionally comprises SEQ ID NO: 3 or SEQ ID NO: 4. NO:4 amino acid sequence; (c) lowering the temperature of the suspension cell culture medium to about 34°C ± 0.1°C and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 1 to infect a HEK293F cell population expressing viral envelope glycoproteins, wherein the rVSV has been engineered so that the rVSV does not express functional envelope glycoproteins; and (d) isolating the rVSV produced by the packaging cell population 23 to 25 hours after infection, wherein the viral envelope glycoproteins are integrated into the viral envelope of the isolated rVSV.

[0122] Examples

[0123] The following examples are provided to provide a person of ordinary skill in the art with a complete disclosure and description of how to prepare and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors consider to be their invention. Efforts have been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but certain experimental errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, molecular weights are average molecular weights, temperatures are in degrees Celsius, and pressures are at or near atmospheric pressure.

[0124] Example 1: Production of high titer of replication-incompetent recombinant vesicular stomatitis virus (rVSV) using suspension HEK293 cells in chemically defined cell culture medium

[0125] use Figure 1 The production scheme shown produces a replication-incompetent form of rVSV without the glycoprotein gene at high titers using a suspension cell line. A specific harvest time was determined to reduce the negative impact of residual transfection reagent on subsequent steps and to eliminate the need for medium changes prior to infection, thereby significantly improving the scalability of the process.

[0126] Materials Included:

[0127] -Cell line: Gibco CTS virus producer cells (suspension cell line derived from HEK293F)

[0128] -Cell culture medium: Gibco CTS LV-MAX production medium

[0129] -Plasmid: pMD2.G

[0130] -Transfection reagent: PEI MAX (40kDa)

[0131] - Virus stock for infection: VSV ΔG:Fluc / GFP

[0132] On day 0, virus production cells were inoculated at 1.7E6 / mL in LV-MAX production medium in a 125 mL shake flask. The shake flask was incubated at 37°C, 8% CO2 and a rocker speed of 125 rpm. 250 system, Sartorius AG) using a temperature set point of 37°C, a pH of 7.0±0.3, a dissolved oxygen level of 30%, and a 22 W / m 3 Comparable experiments were conducted with a stirring power input of 0.01 air volume / liquid volume / minute (VVM), an air injection rate of 0.01 air volume / liquid volume / minute (VVM), and an air overlay of 0.02 VVM with a working volume of 200 mL, as shown in Tables 1 and Figure 2 shown.

[0133] Table 1: Bioreactor parameters

[0134]

[0135]

[0136] On day 1, cells were grown to a target cell density of 3.0E6 / mL. pMD2.G plasmid was diluted in LV-MAX production medium to reach 2.5% of the post-transfection cell culture volume, with a final DNA concentration of 1.5ug / mL. PEI MAX was diluted in LV-MAX production medium to reach 2.5% of the post-transfection cell culture volume, with a PEI MAX to plasmid ratio of 2.5:1. Transfection mixture was prepared by adding diluted PEI MAX to diluted plasmid. The transfection mixture was gently vortexed and then incubated at room temperature for 10 minutes before adding to the shake flask.

[0137] On day 2, cells were counted to determine viable cell density. VSV virus stock was thawed on ice. The virus stock was diluted 1000-fold with cold LV-MAX production medium and the diluted virus stock was directly spiked into the cell culture using a multiplicity of infection (MOI) of 0.01. The temperature of the incubator or bioreactor was lowered to 34°C immediately after infection.

[0138] For production in bioreactors, glucose was fed daily to 5 g / L starting from day 2 when residual glucose dropped to <2.5 g / L.

[0139] On day 4, approximately 48 hours post infection (hpi), crude cell cultures were centrifuged at 3000 x g for 15 min at 4°C to clarify and remove cell debris, and purified VSV material was stored at -80°C until further use.

[0140] The process discussed above yielded infectious titers of approximately 5E8–1E9 pfu / mL, which is comparable to results obtained with adherent cell production systems. Both shake flask and bioreactor experiments yielded comparable titers.

[0141] Example 2: Evaluation of different transfection, infection, culture and harvest parameters for rVSV production in suspension cell culture in terms of viral titer

[0142] Shake flask experiments were performed as discussed in Example 1, and parameters were varied to evaluate the effect on viral titer. In the first set of experiments, the multiplicity of infection (MOI) ratio, amount of transfected DNA, transfection reagent, cell density at transfection, and virus dilution medium and infection medium were evaluated. Figure 3 Among the different parameters tested, the MOI ratio was identified to have the most significant effect on viral titers at 24, 33 and 48 hours post infection (see Figure 3 three columns on the right).

[0143] A second set of shake flask experiments was also performed as discussed in Example 1, with the various parameters shown in Table 2 below. Factors evaluated included the choice of transfection reagent (PEI MAX or FectoVIR-AAV), whether or not a medium change was performed prior to infection, an MOI ratio ranging from 0.001 to 0.01, a post-infection temperature shift ranging from 34°C to 37°C (from an initial temperature of 37°C), and a harvest time ranging from 24 hpi to 96 hpi (24, 36, 48, 72, and 96 hpi were evaluated). The resulting viral titers corresponding to each of these fifteen runs as a function of transfection reagent (PEI MAX or FectoVIR), temperature shift, and harvest time (hpi) are shown in Table 2. Figure 4 Shown in. Figure 5A and Figure 5B The interaction curves of each of the various parameters relative to each other are shown as a function of viral titer (pfu / mL) ranging from 2.78E8 to 4.89E8. Figure 5A and Figure 5B As can be seen from the Figure 2, at 24 hpi, changing the medium before infection and a higher MOI (0.01) were preferred, but at later harvest time points, the effect on viral titer became less significant. Figure 5A and Figure 5B Based on the interaction curves shown, changing the medium prior to infection was deemed unnecessary and a harvest time of 44.4 hpi was preferred when combined with an MOI ratio of 0.01, PEI MAX transfection reagent and a temperature shift from 37°C to 34°C.

[0144] Table 2: Parameters corresponding to 15 runs used to generate rVSV-ΔG

[0145]

[0146] Example 3: Production of high titer of replication-incompetent pseudotyped recombinant vesicular stomatitis virus (rVSV) using suspension HEK293 cells in chemically defined cell culture medium

[0147] use Figure 7 The production scheme shown, using a suspension cell line to produce a replication-incompetent form of rVSV without the glycoprotein gene at high titer. Production was as detailed in Example 1, except that the multiplicity of infection (MOI) was increased from 0.01 to 1, and the harvest time was reduced from about 48 hours post infection (hpi) to about 24 hpi.

[0148] This process produced infectious titers that were more than 3-fold greater than those produced by a comparable adherent cell production system (which produced the same rVSV). Titers were measured using a luciferase assay in Vero cells and the results were Figure 7 Briefly, for titration of pseudotyped viruses, Vero cells were infected with pseudotyped viruses at a certain dilution ratio and the luciferase signal was read 24 hours after infection, where the titer was reported as RLU / mL (RLU, relative light units).

[0149] The scope of the present invention is not limited by the specific embodiments described herein. In fact, various modifications of the present invention, except those described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Claims

1. A method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of packaging cells; (b) transfecting the packaging cells in the suspension cell culture medium with a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein; (c) introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of 0.001 to 3 to infect the population of packaging cells expressing the viral envelope glycoprotein, wherein the rVSV has been engineered such that the rVSV does not express a functional envelope glycoprotein; and (d) isolating the rVSV produced by the packaging cell population 15 to 65 hours after infection, wherein the viral envelope glycoprotein is integrated into the viral envelope of the isolated rVSV.

2. The method of claim 1, wherein the MOI is from 0.001 to 1.

0.

3. The method of claim 1, wherein the MOI is 0.005 to 0.

05.

4. The method of claim 1, wherein the MOI is 0.008 to 0.

012.

5. The method of claim 1, wherein the MOI is about 0.

01.

6. The method of claim 1, wherein the MOI is between 0.5 and 1.

5.

7. The method of claim 1, wherein the MOI is between 0.8 and 1.

2.

8. The method of claim 1, wherein the MOI is about 1.

9. The method of any one of claims 1-5, wherein the rVSV produced by the packaging cells is isolated 40 to 50 hours after infection.

10. The method of any one of claims 1-5, wherein the rVSV produced by the packaging cells is isolated 43 to 47 hours after infection.

11. The method of any one of claims 1, 2, or 6-8, wherein the rVSV produced by the packaging cells is isolated 20 to 30 hours after infection.

12. The method of any one of claims 1, 2, or 6-8, wherein the rVSV produced by the packaging cells is isolated 23 to 25 hours after infection.

13. The method of any one of claims 1-12, wherein the packaging cell is a mammalian cell.

14. The method of claim 13, wherein the packaging cell is a primate cell or a human cell.

15. The method of claim 14, wherein the packaging cells are human embryonic kidney (HEK) cells.

16. The method of claim 15, wherein the HEK cells are HEK293 cells.

17. The method of claim 16, wherein the HEK293 cells are HEK293F cells, HEK293T cells, HEK293SF cells or HEK293S cells.

18. The method of claim 17, wherein the HEK293 cells are HEK293F cells.

19. The method of any one of claims 1-18, wherein the suspension cell culture medium is a serum-free protein-free culture medium.

20. The method of any one of claims 1 to 19, wherein the isolated rVSV is expressed in at least 1 x 10 6 Infectious titers of plaque forming units (pfu) / mL were generated.

21. The method of claim 20, wherein the isolated rVSV is expressed in at least 1×10 7 Infectious titers of pfu / mL were generated.

22. The method of claim 21, wherein the isolated rVSV is expressed in at least 1×10 8 Infectious titers of pfu / mL were generated.

23. The method of claim 22, wherein the isolated rVSV is expressed in at least 5×10 8 Infectious titers of pfu / mL were generated.

24. The method of claim 23, wherein the isolated rVSV is expressed in at least 1×10 9 Infectious titers of pfu / mL were generated.

25. The method of any one of claims 1-19, wherein the isolated rVSV is produced at an infectious titer that is at least comparable to the titer produced by an adherent cell culture control producing the same rVSV.

26. The method of claim 25, wherein the isolated rVSV is produced at an infectious titer that is at least two-fold greater than the titer produced by an adherent cell culture control producing the same rVSV.

27. The method of claim 26, wherein the isolated rVSV is produced at an infectious titer that is at least three times greater than the titer produced by an adherent cell culture control producing the same rVSV.

28. The method of any one of claims 1-27, wherein the viral envelope glycoprotein is vesicular stomatitis virus G protein.

29. The method of any one of claims 1-27, wherein the viral envelope glycoprotein is a class I fusion protein.

30. The method of any one of claims 1-27, wherein the viral envelope glycoprotein is a class II fusion protein.

31. The method of any one of claims 1-27, wherein the viral envelope glycoprotein is a class III fusion protein.

32. The method of any one of claims 1-27, wherein the viral envelope glycoprotein is a coronavirus spike protein.

33. The method of claim 32, wherein the coronavirus spike protein is the spike protein of SARS-CoV-2.

34. The method of claim 33, wherein the coronavirus spike protein comprises the amino acid sequence of SEQ ID NO:

1.

35. The method of claim 33, wherein the coronavirus spike protein comprises the amino acid sequence of SEQ ID NO:

2.

36. The method of any one of claims 1-27, wherein the viral envelope glycoprotein is an Ebola virus glycoprotein.

37. The method of claim 36, wherein the Ebola virus glycoprotein comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:

4.

38. The method of any one of claims 1-27, wherein the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpesvirus, a hepadnavirus, a poxvirus, a paramyxovirus, a rhabdovirus, a bunyavirus, a filovirus, a retrovirus, a hepatitis virus, an influenza A virus, and an influenza B virus.

39. The method of any one of claims 1-38, wherein transfecting the packaging cells comprises using a polyethyleneimine transfection reagent.

40. The method of any one of claims 1-38, wherein transfecting the packaging cells comprises using a liposome transfection reagent or a FectoVIR-AAV transfection reagent.

41. The method of any one of claims 1 to 40, wherein when transfecting the packaging cells, the cell culture medium comprises at least 3 x 10 6 The cell density was 100 packaging cells / mL.

42. The method of any one of claims 1-41, wherein transfecting the packaging cells comprises using a DNA concentration of at least 1.5 μg / mL.

43. The method of any one of claims 1-42, wherein transfecting the packaging cells comprises using a transfection reagent:DNA ratio of about 2 to about 3.

44. The method of claim 43, wherein transfecting the packaging cells comprises using a transfection reagent:DNA ratio of about 2.

5.

45. The method of any one of claims 1-44, wherein the suspension cell culture medium is maintained at a certain temperature during inoculation and transfection, and the temperature of the suspension cell culture medium is reduced to a lower temperature when rVSV is introduced into the suspension cell culture medium.

46. ​​The method of claim 45, wherein the temperature is about 37°C.

47. The method of claim 46, wherein the reduced temperature is from about 32°C to about 36.5°C.

48. The method of claim 47, wherein the reduced temperature is about 35.5°C.

49. The method of claim 47, wherein the reduced temperature is about 34°C.

50. The method of any one of claims 1-49, wherein the suspension cell culture medium is not changed prior to introducing rVSV into the suspension cell culture medium.

51. A method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells, wherein the temperature of the suspension cell culture medium is about 37° C.; (b) transfecting the HEK293 cells in the suspension cell culture medium with a polyethyleneimine transfection reagent and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein; (c) lowering the temperature of the suspension cell culture medium to about 34° C., and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 0.01 to infect a population of HEK293 cells expressing the viral envelope glycoprotein, wherein the rVSV has been engineered such that the rVSV does not express a functional envelope glycoprotein; and (d) isolating the rVSV produced by the packaging cell population 40 to 48 hours after infection, wherein the viral envelope glycoprotein is integrated into the viral envelope of the isolated rVSV.

52. A method for producing a replication-incompetent recombinant vesicular stomatitis virus (rVSV), the method comprising: (a) inoculating a suspension cell culture medium with a plurality of HEK293 cells, wherein the temperature of the suspension cell culture medium is about 37° C.; (b) transfecting the HEK293 cells in the suspension cell culture medium with a polyethyleneimine transfection reagent and a plasmid comprising a nucleic acid molecule encoding a viral envelope glycoprotein to produce a population of packaging cells expressing the viral envelope glycoprotein; (c) lowering the temperature of the suspension cell culture medium to about 34° C., and introducing rVSV into the suspension cell culture medium at a multiplicity of infection (MOI) ratio of about 1 to infect a population of HEK293 cells expressing the viral envelope glycoprotein, wherein the rVSV has been engineered such that the rVSV does not express a functional envelope glycoprotein; and (d) isolating the rVSV produced by the packaging cell population 20 to 28 hours after infection, wherein the viral envelope glycoprotein is integrated into the viral envelope of the isolated rVSV.

53. The method of claim 51 or 52, wherein the viral envelope glycoprotein is a class I fusion protein, a class II fusion protein, or a class III fusion protein.

54. The method of claim 51 or 52, wherein the viral envelope glycoprotein is a coronavirus spike protein.

55. The method of claim 54, wherein the coronavirus is SARS-CoV-2.

56. The method of claim 51 or 52, wherein the viral envelope glycoprotein is an Ebola virus glycoprotein.

57. The method of claim 51 or 52, wherein the viral envelope glycoprotein is a viral envelope glycoprotein of a virus selected from the group consisting of a flavivirus, an alphavirus, a togavirus, a coronavirus, a herpesvirus, a hepadnavirus, a poxvirus, a paramyxovirus, a rhabdovirus, a bunyavirus, a filovirus, a retrovirus, a hepatitis virus, an influenza A virus, and an influenza B virus.

58. The method of any one of claims 51-57, wherein when the HEK293 cells are transfected, the cell culture medium comprises at least 3 x 10 6 The cell density was 100 HEK293 cells / mL.

59. The method of any one of claims 51-58, wherein transfecting the HEK293 cells comprises using a DNA concentration of at least 1.5 μg / mL.

60. The method of any one of claims 51-59, wherein transfecting the HEK293 cells comprises using a transfection reagent:DNA ratio of about 2.

5.

61. The method of any one of claims 51-60, wherein the HEK293 cells are HEK293F cells, HEK293T cells, HEK293SF cells, or HEK293S cells.

62. The method of claim 61, wherein the HEK293 cells are HEK293F cells.